Embecta Corp

Embecta Corp. engages in manufacturing and distributing medical devices used in the treatment of diabetes. It delivers insulin for diabetic patients to improve their lives. The company is headquartered in Parsippany, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Embecta Corp exceeds Q1 revenue expectations and raises 2023 guidance

Embecta Corp delivered strong Q1 performance, raising financial guidance for 2023. Despite challenges in gross margins and increased OpEx spending, the company remains focused on strategic priorities and opportunities for growth.

Embecta Corp reports robust Q2 earnings, eyes growth opportunities

Embecta Corp's Q2 2023 earnings call highlighted strong financial performance, strategic priorities for 2023, and updated guidance. The company is focused on improving diabetes care, revenue diversification, and addressing challenges like the China manufacturing shutdown. Opportunities exist in partnerships, addressing needle reuse, and strategic M&A.

Embecta Corp reports Q3 revenue growth amidst margin challenges

EMBC's Q3 performance showed revenue growth and adjusted net income, despite challenges in U.S. revenue and margin decline
The company's strengths lie in successful product launches, international revenue growth, and future pipeline optimism
Challenges include revenue decline in the U.S., margin pressures, and monitoring competitive threats
Opportunities include demerger process initiation, focus on open-loop system, and improved guidance for 2023

Embecta Corp exceeds revenue expectations in Q4 2023 earnings call

Embecta Corp's Q4 2023 earnings call highlighted revenue growth, strong gross margins, and strategic priorities for fiscal 2024. Despite challenges in TSA expenses and revenue decline projections for 2024, the company remains focused on growth opportunities. Management's commitment to maintaining a 30% adjusted EBITDA margin showcases confidence in the base business.

Embecta Corp surpasses Q1 revenue expectations, raises EPS guidance

Embecta Corp's Q1 performance exceeded expectations, showcasing resilience in its core business and progress in strategic initiatives. While facing challenges related to the ERP transition, the company is well-positioned to leverage opportunities for growth and profitability.

Embecta Corp (EMBC) reports strong Q2 earnings and eyes market expansion

Embecta Corp (EMBC) delivered a robust Q2 performance, exceeding revenue expectations and raising adjusted earnings per share guidance.
The company showcased operational efficiency through successful initiatives like ERP system implementation and distribution network expansion.
While facing challenges in revenue outlook and cash flow management, Embecta remains focused on innovation and market resilience for sustained growth.

Embecta Corp reports Q3 revenue decline but affirms growth outlook

Embecta Corp's Q3 performance reflected revenue decline but strong strategic progress.
The company faces challenges in managing separation costs and addressing revenue decreases.
Opportunities lie in new product introductions, FDA applications, and market development initiatives.

Embecta Corp surpasses 2024 expectations, announces restructuring plan

Embecta Corp's Q4 2024 performance exceeded expectations with revenue growth and EBITDA margin
The company announced a restructuring plan to discontinue the insulin patch pump program for cost savings
Future strategic priorities aim to strengthen core business and expand product portfolio

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

PARSIPPANY, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies, announced today that its Board of Directors declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 14, 2022 to stockholders of record at the close of business on August 26, 2022.

embecta Announces Inaugural Quarterly Cash Dividend

PARSIPPANY, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (NASDAQ: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today announced that it will report its financial results for the third quarter of fiscal year 2022 before the market opens on Monday, August 15, 2022.

embecta Announces Earnings Conference Call Information for the Third Quarter of Fiscal Year 2022

Brookfield Business Corp

Constellation Energy Corp

ESAB Corp

Zimvie

Spinoffs are known for being a mixed bag from the investor's viewpoint. Some of them can unlock the true value of businesses by allowing them to focus on their niches rather than being hampered by underinvestment and undervaluation as part of a bulkier corporation.

Spinoffs Roundup: These Companies Could Unlock Value in 2022

Embecta has a history of profitability, a strong base of revenues, and good free cash flow generation. Diabetes is a large market whose patients are obliged to use insulin for the rest of their lives. This provides a lot of support for the company's economics.

Embecta Is A Winner In A Growing Market

Embecta Corp. (NASDAQ:EMBC ) Q2 2022 Results Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Devdatt Kurdikar - President and Chief Executive Officer Jake Elguicze - Senior Vice President and Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Securities Cecilia Furlong - Morgan Stanley Danielle Antalffy - SVB Securities Mathew Blackman - Stifel Institutional Operator Please stand by. Welcome, ladies and gentlemen, to the second quarter of fiscal year 2022 earnings conference call for Embecta Corp. At this time, all participants have been placed in a listen-only mode.

Embecta Corp. (EMBC) CEO Devdatt Kurdikar on Q2 2022 Results - Earnings Call Transcript

Becton Dickinson and Co's (NYSE: BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ: EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis, down 1.3% on a constant currency basis. Of the decrease, $6.0 million was attributable to unfavorable.

Why Embecta Shares Are Falling Today

PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today reported financial results for the three- and six-month periods which ended March 31, 2022, and provided financial guidance for the last six months of the fiscal year ending September 30, 2022.

Embecta Corp. Reports Second Quarter and First Six Months of Fiscal Year 2022 Financial Results and Provides Financial Guidance for the Last Six Months of Fiscal Year 2022

FRANKLIN LAKES, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ: EMBC) today announced that it will report its financial results for the second quarter of fiscal year 2022 before the market opens on Friday, May 13, 2022.

embecta Announces Second Quarter 2022 Earnings Conference Call Information

Embecta Corp. ( EMBC , Financial) may be new to the public markets, but it is well-established in the diabetes field and now free from the control of Becton, Dickinson and Co. ( BDX , Financial) to implement its ambitious growth plans.

Becton Dickinson Spinoff Embecta Is a Stock to Watch

embecta completes spin-off from BD and lists on NASDAQ as a global leader in diabetes care

News for Embecta Corp Stock (EMBC)